104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Baminercept alfa (BG9924)
- Registration Number
- NCT00664573
- Lead Sponsor
- Biogen
- Brief Summary
To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 339
Inclusion Criteria
- Must be a participant from Study 104RA202 (NCT 00664716)
- Stable dose of Methotrexate for the duration of the study
Exclusion Criteria
- Participants with a significant change in their medical history from their previous BG9924 study
- Any clinically significant infectious illness or serious local infection
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 4 Baminercept alfa (BG9924) Drug: BG9924 - dose administered as per Biogen-Idec protocol Group 2 Baminercept alfa (BG9924) Drug: BG9924 - dose administered as per Biogen-Idec protocol Group 1 Baminercept alfa (BG9924) Drug: BG9924 - dose administered as per Biogen-Idec protocol Group 3 Baminercept alfa (BG9924) Drug: BG9924 - dose administered as per Biogen-Idec protocol
- Primary Outcome Measures
Name Time Method To Observe The Long-Term treatment with BG9924 When Administered to Participants with RA who Previously Participated in a Biogen Idec Study Duration of this study is 18 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Coordinating Research Site
🇬🇧Leeds, Yorkshire, United Kingdom